NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering end-to-end development services, and Advanced Medical Solutions (AMS), an independent developer and manufacturer of innovative tissue-healing technologies, today announced they have entered into a preferred partnership to accelerate the development and commercialization of AMS’s product portfolio.
Under the agreement, Advanced Medical Solutions gains consolidated access to NAMSA’s full suite of services, from regulatory, quality and biological safety consulting, to biocompatibility, chemical characterization, microbiology and package integrity testing, through clinical research spanning study design, trial execution and post-market evidence generation. Bringing these services together under a single partner is designed to reduce handoffs between providers, improve continuity across development programs, and shorten the path from design to market.
“AMS has been a valued partner for many years, and this agreement reflects the strong foundation of trust, collaboration, and shared purpose built over that time. This strategic partnership marks an exciting new chapter in our relationship, bringing together AMS’s innovation in tissue healing and NAMSA’s expertise across preclinical testing, biological safety, regulatory strategy, and clinical planning. Together, we aim to accelerate and streamline the path to market and enhance outcomes for the customers and patients we proudly serve,” said Brian Smith, CEO, NAMSA.
Founded in 1991 and headquartered in Winsford, UK, Advanced Medical Solutions designs and manufactures surgical and advanced wound care medical devices marketed under brands including LIQUIBAND, RESORBA, ActivHeal, VITAClip, IFABOND, LIQUIBANDFIX8, LIQUIFIX and Seal-G. Its portfolio spans tissue adhesives, sutures, haemostats, internal fixation devices and sealants, alongside advanced wound care dressings, with products sold in more than 100 countries.
MedTech manufacturers continue to face evolving regulatory requirements and rising demands for clinical and biological safety evidence. More stringent expectations can extend development timelines, increase costs and delay patient access. NAMSA’s integrated model gives sponsors a single partner across preclinical, testing, regulatory and clinical services, helping them manage risk earlier and move products forward more efficiently.
“Formalising this preferred partnership is a natural evolution of the trust and collaborative success our teams have built over many years. By integrating NAMSA’s comprehensive preclinical and clinical expertise with our surgical and advanced wound care pipeline, we gain the expertise needed to clear regulatory hurdles and bring our technologies to patients much faster,” Advanced Medical Solutions.
For similar news, please visit these web pages:
Vantedge Medical appoints Walter Morse as Chief Operating Officer
Robo.ai Subsidiary Neurovia AI Launches NeuroStream Technology Platform
